Understanding Real-Time Alerts vs Data Snacks
Based on client feedback, we've clarified the distinction between Real-Time Alerts and Data Snacks to better serve different user needs:
| Real-Time Alerts | Data Snacks | |
|---|---|---|
| Purpose | High-priority, time-sensitive competitive intelligence that requires immediate attention | Broader market insights and analysis that provide context but aren't time-critical |
| Curation | Human-curated by CI analysts, with strategic release timing | More automated, with less tailoring to specific client needs |
| Frequency | As needed, when significant events occur | Regular cadence, regardless of event significance |
| Content | Focused on specific events (trial announcements, approvals, etc.) | Broader analysis, trends, and market landscape information |
| User Action | Often requires immediate attention or action | Reference material for planning and context |
This distinction helps ensure users receive the right information in the right format at the right time, reducing noise and increasing relevance.
Real-Time Alerts Filters
Real-Time Alerts
FDA grants priority review for Competitor X's new multiple myeloma therapy
High PriorityThe FDA has granted priority review for Competitor X's novel BCMA-targeted therapy for relapsed/refractory multiple myeloma. The PDUFA date is set for October 15, 2025, which could lead to an approval ahead of similar therapies in development.
Positive Phase 3 results for Competitor Y's IL-23 inhibitor in psoriatic arthritis
Medium PriorityCompetitor Y announced positive topline results from their Phase 3 trial of their IL-23 inhibitor in psoriatic arthritis. The study met its primary endpoint of ACR20 response at week 24 with statistical significance (p<0.001) compared to placebo.
New publication in NEJM on long-term safety of TREMFYA in psoriasis
StandardA new publication in the New England Journal of Medicine reports on the 5-year safety data for TREMFYA in moderate-to-severe plaque psoriasis, showing a favorable long-term safety profile consistent with previous reports.
Competitor Z initiates Phase 2 trial for novel treatment-resistant depression therapy
StandardCompetitor Z has initiated a Phase 2 clinical trial for their novel NMDA receptor modulator in treatment-resistant depression. The trial will enroll approximately 120 patients across 15 sites in the US and Europe.
© 2025 CI Agent. All rights reserved.